Sales up 16.3%
The latest figures
All key numbers (36) From EDGAR
| EPS (ttm) | 6.10 | Sales (ttm) | 3.5B | Net income (ttm) | 1.0B | Sales growth | +16.3% | EPS growth | +25.9% | Sales Q/Q | +17.6% |
| Free cash flow | - | Gross margin | 75.0% | Oper. margin | 29.9% | Net margin | 29.3% | FCF margin | - | ROE | 13.7% |
| ROA | 11.2% | R&D / sales | 24.0% | Dividend | - | Debt/Eq | - | Curr. ratio | 5.46 | Cash | 1.8B |
| Op. cash flow (ttm) | 1.7B | Quick ratio | 5.46 | ROIC | 9.4% | Tax rate | 23.9% | Stock pay / sales | 14.8% | Shares out. | 161.9M |
| Shares Y/Y | +1.1% | Book / share | 45.90 | Cash / share | 11.19 | Sales / share | 21.36 | Asset turnover | 0.38 | Days sales out. | 144 |
| Sales 3Y CAGR | +14.0% | Sales 5Y CAGR | +16.9% | EPS 3Y CAGR | +21.9% | EPS 5Y CAGR | +18.2% | Employees | 7,928 | Sales / employee | 436K |
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Changes in the numbers
FY2026 against FY2025-
Operating margin widened to 28.7%25.2% → 28.7% · Operating income / revenue · 10-K ↗
VEEV against Health care peers
Ten years, side by side → · All 60 →Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How
Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.
| Company | Revenue (ttm) | Sales growth | Gross margin | Net margin | ROE | FCF margin | Debt / equity |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | $3.5B | +16.3% | 75.0% | 29.3% | 13.7% | - | - |
| ALGN Align Technology | $4.2B | +0.9% | 69.1% | 11.8% | 11.4% | 14.5% | - |
| CRL Charles River Laboratories | $4.0B | -0.9% | - | 1.0% | 1.2% | 10.0% | 0.76 |
| WST West Pharmaceutical Services | $3.4B | +6.3% | 37.6% | 18.8% | 21.5% | 13.3% | 0.07 |
| PODD Insulet Corporation | $3.2B | +30.7% | 71.9% | 13.4% | 27.1% | 8.2% | 0.61 |
| RVTY Revvity | $2.9B | +3.7% | - | 8.2% | 3.3% | 19.2% | 0.44 |
From $1.9B of sales to $427.4M of profit
FY2021, from the 10-K income statementSwipe sideways for the whole flow →
From $2.2B of sales to $487.7M of profit
FY2023, from the 10-K income statement and revenue by productSwipe sideways for the whole flow →
From $2.4B of sales to $525.7M of profit
FY2024, from the 10-K income statementSwipe sideways for the whole flow →
From $2.7B of sales to $714.1M of profit
FY2025, from the 10-K income statementSwipe sideways for the whole flow →
From $3.2B of sales to $908.9M of profit
FY2026, from the 10-K income statement and revenue by productSwipe sideways for the whole flow →
Where each $100 of sales went
- Cost of revenue
- R&D
- Sales, admin & other
- Tax, less other income
- Net profit
Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →
Profitability
3 of 4- ✓Net margin above the peer median29.3% vs 9.6%
- ✓Gross margin up over 5 years72.1% → 75.5%
- !Return on equity below 15%13.7%
- ✓A profit in every one of 10 years
Cash and shareholders
2 of 3- ✓Free cash flow positive in every one of 4 years$434.3M last year
- !Share count up over 5 years+3.9%
- ✓Cash from operations above net income$1.4B vs $908.9M
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Revenue and net income, FY2017 to FY2026
Revenue 3.2B Net income 908.9MFrom XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →
Income statement, balance sheet and cash flow
VEEV's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Revenue by product or service
year to Jan 31, 2026| Revenue | Share | vs year before | |
|---|---|---|---|
| Total subscription | 2.7B | 84.0% | +17.5% |
| R&D and Quality Solutions | 1.4B | 44.6% | +20.9% |
| Commercial Solutions | 1.3B | 39.4% | +13.8% |
| Total professional services and other | 511.1M | 16.0% | +10.6% |
| R&D and Quality Solutions | 321.8M | 10.1% | +16.3% |
| Commercial Solutions | 189.3M | 5.9% | +2.2% |
10-K 0001393052-26-000014, segment and revenue notes (XBRL).
Revenue by region
year to Jan 31, 2026| Revenue | Share | vs year before | |
|---|---|---|---|
| North America | 1.9B | 59.6% | +17.4% |
| Europe | 939.6M | 29.4% | +18.8% |
| Asia Pacific | 280.2M | 8.8% | +5.4% |
| Other international | 72.2M | 2.3% | +5.5% |
10-K 0001393052-26-000014, segment and revenue notes (XBRL).
Income statement
From EDGARBalance sheet
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2021 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | 217.6M | 320.2M | 551.0M | 476.7M | 730.5M | 1.1B | 886.5M | 703.5M | 1.1B | 1.4B |
| Short-term investments | - | 441.8M | 539.2M | 610.0M | 933.1M | 1.2B | 2.2B | 3.3B | 4.0B | 5.1B |
| Receivables | 182.8M | 224.7M | 303.5M | 389.7M | 564.4M | 631.1M | 703.1M | 852.2M | 1.0B | 1.3B |
| Current assets | 711.9M | 1.0B | 1.4B | 1.5B | 2.3B | 3.1B | 4.0B | 5.0B | 6.3B | 8.0B |
| Property & equipment | 49.9M | 52.3M | 55.0M | 54.8M | 53.6M | 54.5M | 49.8M | 58.5M | 55.9M | 70.3M |
| Goodwill | 95.8M | 95.8M | 95.8M | 438.5M | 436.0M | 439.9M | 439.9M | 439.9M | 439.9M | 439.9M |
| Total assets | 917.4M | 1.2B | 1.7B | 2.3B | 3.0B | 3.8B | 4.8B | 5.9B | 7.3B | 9.0B |
| Accounts payable | 5.7M | 6.9M | 9.1M | 19.4M | 23.3M | 20.3M | 41.7M | 31.5M | 30.4M | 37.6M |
| Current liabilities | 246.8M | 306.2M | 401.0M | 551.2M | 716.0M | 840.8M | 1.0B | 1.2B | 1.4B | 1.6B |
| Total liabilities | 264.7M | 324.1M | 416.0M | 606.2M | 779.7M | 904.8M | 1.1B | 1.3B | 1.5B | 1.8B |
| Shareholders' equity | 678.2M | 906.2M | 1.2B | 1.7B | 2.3B | 2.9B | 3.7B | 4.6B | 5.8B | 7.2B |
| Retained earnings | 212.9M | 389.4M | 619.2M | 919.7M | 1.3B | 1.7B | 2.2B | 2.7B | 3.5B | 4.4B |
Cash flow
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2021 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 144.0M | 233.4M | 310.8M | 437.4M | 551.2M | 764.5M | 780.5M | 911.3M | 1.1B | 1.4B |
| Capital spending | 6.9M | 9.6M | 8.4M | 3.1M | - | - | - | - | - | - |
| Free cash flow | 137.1M | 223.8M | 302.4M | 434.3M | - | - | - | - | - | - |
| Stock-based pay (added back) | 40.8M | 54.0M | 76.4M | 115.9M | 185.0M | 234.6M | 351.9M | 393.7M | 437.4M | 472.7M |
| Buybacks | - | - | - | - | - | - | - | 0 | 0 | 169.9M |
| Acquisitions | - | 0 | 0 | 448.2M | 0 | 7.8M | 0 | 0 | - | - |
| Investing cash flow | -96.8M | -154.5M | -103.9M | -516.9M | -333.6M | -346.2M | -1.0B | -1.1B | -700.1M | -1.1B |
| Financing cash flow | 38.0M | 20.8M | 25.9M | 10.0M | 33.8M | -4.1M | -19.4M | -16.2M | 26.1M | -9.3M |
Stock-based pay and leases
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2021 | FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 40.8M | 54.0M | 76.4M | 115.9M | 185.0M | 234.6M | 351.9M | 393.7M | 437.4M | 472.7M |
| Stock-based pay / revenue | 7.4% | 7.8% | 8.9% | 10.5% | 12.6% | 12.7% | 16.3% | 16.7% | 15.9% | 14.8% |
| Operating lease cash paid | - | - | - | 7.7M | 11.4M | 13.8M | 12.9M | 10.3M | 12.5M | 9.5M |
| Finance lease principal paid | - | - | - | 984K | - | - | - | - | - | - |
| Right-of-use assets | - | - | - | 49.1M | 56.9M | 49.6M | 55.3M | 45.6M | 63.9M | 75.6M |
| Operating lease liabilities | - | - | - | 53.4M | 62.7M | 54.6M | 61.0M | 55.8M | 75.8M | 95.9M |
| Finance lease liabilities | - | - | - | 1.4M | - | - | - | - | - | - |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.